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Abstract Recently, thioridazine (10-[2-(1-methyl-2-
piperidyl) ethyl]-2-methylthiophenothiazine), a well-
known anti-psychotic agent was found to have anti-cancer
activity in cancer cells. However, the molecular mecha-
nism of the agent in cellular signal pathways has not been
well defined. Thioridazine significantly increased early-
and late-stage apoptotic fraction in cervical and endome-
trial cancer cells, suggesting that suppression of cell growth
by thioridazine was due to the induction of apoptosis. Cell
cycle analysis indicated thioridazine induced the down-
regulation of cyclin D1, cyclin A and CDK4, and the
induction of p21 and p27, a cyclin-dependent kinase
inhibitor. Additionally, we compared the influence of thi-
oridazine with cisplatin used as a control, and similar
patterns between the two drugs were observed in cervical
and endometrial cancer cell lines. Furthermore, as expec-
ted, thioridazine successfully inhibited phosphorylation of
Akt, phosphorylation of 4E-BP1 and phosphorylation of
p70S6K, which is one of the best characterized targets
of the mTOR complex cascade. These results suggest
that thioridazine effectively suppresses tumor growth
activity by targeting the PI3K/Akt/mTOR/p70S6K signal-
ing pathway.
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thiophenothiazine), a phenothiazine derivative, is a potent
anti-psychotic and anti-anxiety agent belonging to the phe-
nothiazine drug family. It is widely used to treat psychotic
disorders such as psychosis and schizophrenia. Thioridazine
may interact with other drugs which can cause drowsiness,
such as alcohol, anti-depressants, muscle relaxants, anti-his-
tamines, pain relievers and anxiety medicines. In case of
advanced cancer, the drug has been used to treat cancer-
related sweating [1, 2] and depression [3]. However, there
have been several previous reports showing that the drug may
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cause serious side effects and a reversal of drug resistance, as
well as, neuroleptic malignant syndrome [4–8]. Although
several mechanisms, including inhibition of P-glycoprotein
[9], DNA damage [10], or anti-oxidant activity [11], have
been proposed to explain the anti-cancer effects of the drug,
the true mechanism of thioridazine’s anti-cancer effects have
been unclear.
Recently, a group of researchers observed that the anti-
proliferative effect of chlorpromazine, another phenothia-
zine derivative, can be blocked by wortmannin, a selective
PI3K inhibitor [12]. Thioridazine use may lead to the
development of symptoms that resemble Parkinson’s dis-
ease, but these symptoms are not directly caused by
Parkinson’s. In a study, we demonstrated the similiarities
of the gene expression profile between thioridazine and
known PI3K/Akt pathway inhibitors using the gene-
expression-based query [13], while also showing that
thioridazine could exhibit PI3K/Akt pathway inhibition in
ovarian cancer cells.
Phosphatidylinositol 3-kinase (PI3K)/Akt signal trans-
duction plays an important role in cell growth via inhi-
bition of apoptosis in various types of human cancers
[14–17]. Activation of Akt also promotes tumor metas-
tasis and invasion, antagonizes cell-cycle arrest, angio-
genesis, and phosphorylates mTOR (mammalian target of
rapamycin) protein kinase. The mTOR pathway is medi-
ated by a wide variety of cellular signal communications
which include hormones, such as insulin and growth
factors, nutrients, such as amino acids and glucose, and
cellular stress conditions. The phosphorylation of Akt is
modulated by phosphatidylinositol-3,4-bisphosphate and
phosphatidylinositol-3,4,5-triphosphate, which are gener-
ated by (PI3K) [18]. PI3K is an activator of Akt, which
consists of catalytic subunits (110 kDa) and regulatory
subunits (85 kDa) [19]. A principal pathway that signals
via mTOR is the PI3K/Akt signaling pathway, which is
critically involved in the regulation of cell proliferation
and survival. mTOR may also indirectly influence the
phosphorylation condition of 4E-BP1 by modulating the
activity of PP2A (Protein Phosphatase-2A). The second
step effector, which is down-stream of mTOR, is the
p70S6K serine/threonine kinase. After processing a cell
proliferative up-stream signal mediated by the PI3K/Akt
pathway, mTOR phosphorylates and activates p70S6K.
mTOR plays a key role in the regulation of cell cycle
progression, which includes protein synthesis, tumor
growth, and angiogenesis [20–22].
In the present study, we estimated the anti-proliferative
effect of thioridazine in human cervical and endometrial
cancer cells, and determined the underlying molecular
mechanisms. In addition, here we showed that thioridazine
is a potent suppressor of cellular signaling pathways of
PI3K-Akt-mTOR.
Materials and methods
Cell culture, antibodies, and chemicals
Human cervical (HeLa, C33A and Caski) and endometrial
(HEC-1-A and KLE) cancer cell lines were maintained in
DMEM (Life Technologies, Gaithersburg, MD) and
RPMI1640 added with either 10 % heat-inactivated fetal
bovine serum (FBS), penicillin (100 U/ml), or streptomy-
cin (100 lg/ml), at 37 C in a humidified atmosphere
containing 5 % CO2. The following antibodies were used in
this study: anti-Akt, anti-phospho-specific Akt, anti-PI3K,
anti-phospho-specific PI3K, anti-cyclin A, anti-cyclin B1,
anti-cyclin D1, anti-CDK1, anti-CDK2, anti-CDK4 (Santa
Cruz Biotechnology, Santa Cruz, CA), anti-caspase-3, anti-
Bcl-2, anti-Bcl-xL, anti-Bax, anti-mTOR, anti-phospho-
mTOR, anti-p70S6K, and anti-phospho-p70S6K(Thr 421)
(BDPhamingen, San Diego, CA), anti-p21 and anti-p27
(Oncogene, San Diego, CA), anti-4E-BP1 and anti-phos-
pho-4E-BP1 (Cell Signaling) and anti-b-actin (Sigma).
Rapamycin was purchased from Cell Signaling (Berverly,
MA). Other chemicals and anticancer drugs were pur-
chased from Sigma (St. Louis, MO).
Cell viability assays
The viability of cell growth was determined using 3-(4,5-
dimethylthiazol-2-yl)-2.5-diphenyl-2H-tetrazolium bromide
(MTT) assays. Briefly, cell lines were grown in DMEM
medium containing 10 % FBS. The cells were plated at a
density of 3.4 9 103 cells/well in 96-well plates. After 24 h,
fresh medium containing 10 % FBS and 20 ll of MTT solu-
tion (Sigma, 5 mg/ml) was added to each well. Each well was
then incubated for an additional 4 h at 37 C. The amount of
MTT-formazan generated was measured as the absorbance by
using a microculture plate reader at 540 nm. Each individual
measurement was repeated three times.
Cell cycle analysis and apoptosis assays
Cancer cells were distributed onto six-well plates and then
treated with thioridazine (15 lM) for 24 h, respectively. To
evaluate apoptotic cells, the nuclei were fixed in methanol,
stained with 2 lg/ml of 4,60-diamidino-2-phenylindole
(DAPI, Boehringer Mannheim, Mannhein, Germany) for
15 min at 37 C, rinsed twice with PBS, and monitored
under a fluorescence microscope (Zeiss; Switzerland). All
experiments were carried out in triplicate. Subsequently,
for the analysis of the DNA content using flow cytometry,
each cell line was maintained at a density of 3.2 9 105–
4.1 9 105 cells in 60-mm plates. After treatment with
thioridazine, the cells were harvested, rinsed with ice-cold
PBS, and fixed with ice-cold 70 % ethanol. The cells were
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centrifuged for 5 min at 1,0009g and resuspended in PBS
containing 5 mM of EDTA and RNase A (1 mg/ml). After
incubation for 1 h at 37 C, the cells were treated for
15 min with fluorescein isothiocyanate (FITC)-labeled
Annexin V and propidium iodide (PI), according to the
supplier’s protocols (Boehringer Mannheim, Mannhein),
and then were analyzed with a flow cytometer (FACScal-
ibur, Becton–Dickinson, Franklin Lakes, NJ).
Measurement of caspase-3 activity
For caspase-3 activity, cells (2.5 9 106) were grown in
either the absence or presence of thioridazine at 37 C
for 24 h. Caspase-3 activity was measured using an
actyl-DEVD-7-amino-4-trifluoromethyl coumarin as the
substrate, according to the manufacturer’s instructions
(BDPharmingen, San Diego). In brief, the cells were placed
with VP-16 (100 lg/ml) for 24 h, lysed in lysis buffer, and
centrifuged for 25 min at 12,0009g at 4 C. The activity
was quantified in the supernatant fraction according to its
proteolytic cleavage of the colorimetric substrate by use of
a Spectramax 340 microplate reader (Molecular Devices,
Sunnyvale) in fluorescence mode, with excitation at
405 nm and emission at 505 nm.
For assay of PARP cleavage, we carried out the proce-
dures as described in the previous study [23, 24]. In brief,
50 lg of protein was placed with 60 lM biotinylated NAD
in a 50 ll final volume of PARP reaction buffer (50 mM
Tris–HCl, pH 8.0 and 25 mM MgCl2) at 37 C for 1 h. The
reaction was stopped by the addition of SDS loading dye
buffer, and the products were separated using SDS-PAGE
gel and autoradiography.
Immunoblotting analysis
After treatment with thioridazine, cells were harvested by
centrifugation. Cell extracts were prepared by washing
cells with PBS, and cells were lysed in a buffer containing
protease inhibitor. The protein yield was measured using
the Bio-Rad protein assay kit. Equal amounts of protein
were loaded, separated by SDS-PAGE gel, and then
transferred to polyvinylidene difluoride membrane. After
blocking, the membranes were placed at room temperature
for 1 h with primary antibodies applied. The blots were
washed thrice in wash buffer and incubated with the
appropriate horseradish peroxidase-linked secondary anti-
bodies. The immunoreactive bands were developed using
the ECL detection system.
Luciferase assays
Luciferase activity was carried out with a dual luciferase
reporter assay kit (Promega, Madison, WI). Cancer cells
were transfected by using the vector DNA containing
p21-, p53- and Bcl-2-luciferase, in which the luciferase is
expressed under each promoter control. The reporter
plasmid, Bcl-2-Luc and p53-Luc were kindly provided by
Dr. K. Park (Samsung Medical Center, Korea), and p21
promoter reporter construct by J. Park (Yonsei Univer-
sity, Korea). Data presented are representative of three
replicate experiments. Briefly, cells at 80 % confluency
were transiently transfected with each indicated reporter
construct. After lysis with Reporter Lysis Buffer (Pro-
mega), lysates were cleared with centrifugation for
15 min at 14,000 rpm and cell extracts were incubated
with the luciferase substrate reagent for 30 min at room
temperature. Then, a 5 ll aliquot of each sample was
transferred into the MicroLumat Plus LB96V lumino-
meter. The ratio was normalized for the Renilla lucifer-
ase activity to correct for variations in transfection
efficiency.
PI3K assays
Enzyme assays were carried out as described previously
by Fruman et al. [25]. In brief, cells were plated at a
density of 1.8 9 106 cells. After overnight incubation,
cells were treated with either 15 lM thioridazine or
wortmannin and LY294002 as a PI3K inhibitor, or left
without treatment as the control for 24 h. Cells were lysed
in 1 % NP-40 lysis buffer containing 20 mM Tris–HCl
(pH 7.5), 100 mM NaCl, 1 mM EDTA, 1 mM MgCl2, 1
% NP-40, 1 mM phenylmethylsulfonyl fluoride, and
0.1 mM sodium orthovanadate. The lysates were centri-
fuged at 4 C for 15 min at 20,0009g and the superna-
tants were used as the cell lysate. To immunoprecipitate
PI3K, proteins were incubated for 1 h at 4 C with anti-
p85 antibody, followed by incubation with protein
A-agarose beads for an additional 1 h at 4 C. Imm-
nunoprecipitates were incubated with kinase reaction
buffer mix containing 200 lg/ml of phosphatidylinositol
and 2 lCi of [-32P] ATP per assay mixture at 37 C for
15 min. The reaction products were developed using
autoradiography and the radioactive lipids were quantified
by liquid scintillation counting.
Statistical analyses
All data values were presented as either the mean ± SD
(mean ± standard deviation) or means ± SEM (means ±
standard error of means). Statistical comparisons were
measured using Student’s t-test. Statistical analyses were
carried out by using STATA software ver. 10.0 (StataCorp,
College Station, TX). P values of\0.05 (*) were considered
significant.
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Results
Thioridazine regulates the cell proliferation
and apoptosis
In order to examine the effect of thioridazine-induced
inhibition of cellular proliferation in cervical and endo-
metrial cancer cells, cells were treated with thioridazine
(15 lM). As shown in Fig. 1a, cell viability of the cer-
vical (HeLa, Caski and C33A) and endometrial (HEC-1-A
and KLE) cancer cells were reduced by treatment of
thioridazine. To confirm that the reduction in the cell
numbers was reflective of cell death, flow cytometric
detection was performed using labeled annexin V
(Fig. 1b). Among all tested cell lines except KLE cells,
cells treated with thioridazine demonstrated significantly
increased early- and late-stage apoptotic fraction, which
suggests that cell growth suppression by thioridazine was
due to increased apoptosis. In addition, we compared the
influence of thioridazine with cisplatin and similar apop-
totic patterns between the two agents were observed in
HeLa cells.
Subsequently, we assessed whether this effect of thio-
ridazine is associated with an activation of caspase-3. In
western blot analysis, as well as activity, thioridazine
clearly induced activation of caspase-3. Especially in HeLa
and HEC-1-A, the degree of caspase-3 activity was com-
parable to that of cisplatin (Fig. 1c). Additionally, cleavage
of caspase-3 was also confirmed in response to thioridazine
in HeLa and HEC-1-A, indicating that caspase-3 activation
was mediated by cleavage of caspase-3 (Fig. 1d). We also
compared the potency of thioridazine in cell proliferation
inhibition with those of wortmannin and LY294002. As
shown in Supplementary Fig. 1, proliferation of cells
treated with wortmannin or LY294002 was inhibited to 53
and 52 % lower than the control in HeLa cells. In addition,
thioridazine had more cell growth inhibitory effect than
either of these two known PI3K inhibitors. Finally, the
cleavage and activation of caspase-3 resulted in the char-
acteristic proteolysis, e.g., cleavage of poly (ADP-ribose)
polymerase (PARP) of HeLa and HEC-1-A after treatment
of thioridazine (Fig. 1e). These results corresponded to our
previous observation that thioridazine may inhibit cellular
proliferation and induce apoptosis.
Thioridazine-induced alteration of cell cycle
modulators
Since we previously found that thioridazine may modulate
the regulation of cell cycle progression by interfering with
the PI3K/Akt pathway and induces G1 cell cycle arrest, we
then investigated the influence of thioridazine treatment
on changes to the cell cycle regulatory proteins using
immunoblotting assays. As expected, we observed that
thioridazine dramatically inhibited the expression of cyclin
D1 and CDK4. In addition, p27 protein expression was
enhanced after treatment of thioridazine, suggesting CDK
inhibitor p27 has a major role in G1 cell cycle arrest
induced by thioridazine. We also observed reduced
expression of cyclin A and increased level of p21, which
was consistent with a G1 cell cycle arrest. The expression
of cyclin A and CDK2, which regulates transition from S or
M phase, was decreased with the treatment of thioridazine.
CDK1 and cyclin B1 regulate progressions from G2 to M
phase, and were also inhibited (Fig. 2a).
Since p21 is the transcriptional target of p53, the
expression of p53 was explored (Fig 2b). Expression level
of p53 was increased after treatment of thioridazine along
with Bax. In contrast, expression of anti-apoptotic protein
Bcl-2 and Bcl-xL was decreased. Furthermore, by using
luciferase reporter assay, we confirmed that thioridazine
increased transcription of p53 (Fig. 2c). In the Supple-
mentary Fig. 2, p21 and p27 more enhanced the expression
levels of wortmannin-treated HeLa cells when compared
with that of thioridazine-treated cells as expected. Also,
treatment of thioridazine or wortmannin significantly
increased the levels of Bax and p53 expression in a
time-dependent manner. Thus, it can be speculated that
thioridazine induces G1 cell cycle arrest by increasing
transcription of p53 and its transcriptional target, p21.
Suppression of PI3K/Akt/mTOR/p70S6K
phosphorylation by thioridazine in cervical
and endometrial cancer cells
We tested whether thioridazine could induce inhibition of
PI3K activity in HeLa and HEC-1-A cells. After treatment
with EGF (50 ng/ml, 6 h), cell lysates were immunopre-
cipitated using anti-p85 antibody with or without thiorid-
azine treatment. After treatment of thioridazine, cells
showed significantly inhibited phosphorylation of PI3K.
This inhibitory activity was comparable to that of two well-
known PI3K inhibitor, wortmannin and LY294002
(Fig. 3a). The inhibition of PI3K in the two cells resulted in
inhibition of Akt, which is one of the major downstream
targets of PI3K. As expected, thioridazine also successfully
inhibited phosphorylation of Akt (Ser 473) and phosphor-
ylation of 4E-BP1 (Fig. 3b), one of the best characterized
targets of the mTOR complex. Also, treatment with thio-
ridazine decreased the level of phosphorylated Akt (Thr
308) as well as the level of phosphorylated GSK-3b (Ser 9)
within 3–6 h, whereas wortmannin and LY294002 signif-
icantly inhibited the level of phosphorylated protein
within 6 h (Supplementary Fig. 3). When thioridazine
was co-treated with rapamycin, inhibitor of mTOR,
we observed that they exerted additive effects in the
992 Apoptosis (2012) 17:989–997
123
deactivation of p-4E-BP1. These results suggest that con-
firm our former hypothesis that thioridazine is a potent
inhibitor of PI3K activity.
Finally, after treating the five cell lines (three cervical
and two endometrial) with EGF (50 ng/ml, 6 h), we examined
the effect of thioridazine on the down-stream signaling
Fig. 1 Treatment of thioridazine inhibits cellular proliferation and
activates caspase-dependent pro-apoptotic activity. a Effect of
treatment with thioridazine (15 lM) was analyzed by 3-(4,5-dimeth-
ylthiazol-2-yl)-2.5-diphenyl-2H-tetrazolium bromide (MTT) assays.
Inhibition of cellular proliferation by cisplatin (20 lM) in HeLa cells
was also illustrated for comparison. b Early- and late-stage apoptosis
induced by thioridazine was analyzed by fluorescein isothiocyanate
(FITC)-labeled Annexin V assay. c Caspase-3 enzymatic activity after
treatment of thioridazine was determined using actyl-DEVD-7-
amino-4-trifluoromethyl coumarin as the substrate. d, e Caspase-3
and PARP cleavages induced by cisplatin and thioridazine treatments.
Soluble protein extracts were conducted by immunoblotting for
cleaved caspase-3 and cleaved PARP. b-actin was used as an equal
loading control
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components in the PI3K/Akt pathway. Thioridazine inhibited
the phosphorylation of mTOR on Ser 2448 residue and
p70S6K on Thr 421 residue, a downstream target of mTOR
(Fig. 4). Taken together, our results support the idea that thi-
oridazine targets the Akt/mTOR/p70S6K signaling pathway,
which leads to the inhibition of tumor growth and metastasis.
Discussion
The current study has shown that thioridazine inhibits
cellular proliferation through the induction of G1 cell cycle
arrest and cellular apoptosis and that the anti-proliferative
effect of thioridazine on cervical and endometrial cells may
result from the inhibition of PI3K/Akt/mTOR/p70S6K
signaling pathways by thioridazine, which corresponds
with our previous study [26].
The PI3K/Akt/mTOR/p70S6K signaling pathways play
a pivotal role in the physiological functions of human
malignant tumors. PI3K modulates signaling pathways
implicated in cell growth, apoptosis, or both. Regulatory
factors of this pathway are frequently deregulated in an
extensive number of tumor types, making it an attractive
target for tumor therapy [27]. Akt activity is modulated by
PI3K, which recruits Akt to the cell membrane, permitting
its activation by PDK1 [28]. Akt activation induces cell
cycle progression, survival, migration and metabolism
through phosphorylation of various physiological factors.
Activation of PI3K and Akt are reported to occur in
ovarian, thyroid, breast and pancreatic tumor [29].
Based on these findings, the PI3K/Akt pathway is
believed to be a promising therapeutic target for the
treatment of cancer. Moreover, a body of evidence indi-
cates that inhibition of PI3K/Akt pathway may inhibit cell
growth, and increase the cytotoxic effect of conventional
chemotherapeutic agents in many solid tumors [17, 30–34].
In addition, mTOR, a major down-stream target of PI3K/
Akt pathway, is well-known as an essential regulator of
tumor growth and cell proliferation, protein synthesis, and
the modulation of signals in various signaling pathways
[27, 35].
Thus, our data suggest that thioridazine alone or with
conventional cytotoxic agents may be worth to be tested
in further studies as an effective therapeutic option.
Fig. 2 Effect of thioridazine on
the expression of cell cycle
regulatory protein and
apoptosis-related genes.
a Soluble protein extracts were
subjected by western blot for the
indicated proteins (p21, p27,
cyclin A, B1, D1, CDK4, CDK2
and CDK1). b Expression of
Bcl-2 family genes (Bcl-2, Bcl-
xL, Bax and p53) were tested by
using immunoblotting. b-actin
was used as loading control.
c After treatment with
thioridazine, transfection with
p53-, p21- and Bcl-2-luciferase,
respectively. After collection by
centrifugation, mixed with the
reaction substrate and the effect
on luciferase activity were
measured by using a
luminometer. All experiments
were performed at least three
times with similar results
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The anticancer effect of thioridazine had been demon-
strated in vivo by using a mouse model system [36]. In
addition, although there has been no well-designed human
trial, there was a case report of successful treatment with
high-dose thioridazine in a cervical cancer patient [37].
Moreover, thioridazine has already been used in cancer
patients for managing depression and psychosis [38].
However, because the drug is not free from side effects,
such as cardiac toxicity, movement disorder, and central
nervous system effect, the toxicity of high-dose
thioridazine should be carefully evaluated. In addition,
biologically achievable dose and specificity of the drug
should be determined further. Since there have been several
case reports addressing the clinical efficacy of phenothia-
zine derivatives in cancer patients [37, 39], the clinical use
of thioridazine as a targeting agent of PI3K/Akt/mTOR
signaling pathway may not be unrealistic when these
concerns are resolved by further research.
In summary, our data show that thioridazine can inhibit
the PI3K/Akt/mTOR/p70S6K signaling pathway and exert
Fig. 4 Western blot analysis of down-stream components in the Akt
signaling pathways with thioridazine-treated cervix cancer and
endometrial cancer cells, respectively. After treatment of thioridazine,
total cells lysates were prepared and investigated for phospho-
mTOR(Ser2448) and phospho-p70S6K(Thr421) protein levels by
immnunoblot analysis. Unphosphorylation protein was used as an
equal loading control (indicated as mTOR and p70S6K)
Fig. 3 Thioridazine promotes pro-apoptotic signaling through inhi-
bition of p-Akt activation. a Effect of thioridazine and other PI3K
inhibitors on PI3K activity was assayed by immunoblotting for total
PI3K and phosphorylated PI3K. The reaction products were visual-
ized using autoradiography and liquid scintillation counting. b HeLa
and HEC-1-A cells were treated with each chemical drugs and
analyzed for the indicated proteins by immunoblotting for total Akt/
phosphorylated Akt (p-Ser 473 and p-Thr 308), GSK-3b/phosphor-
ylated-GSK-3b (p-Ser 9) and 4E-BP1/phosphorylated-4E-BP1.
Results shown are representative of three independent experiments
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cytotoxic effect on cervical and endometrial cancer cells by
inducing cell cycle arrest and apoptosis. The usefulness of
this agent in cancer treatment should be explored in future
research.
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